Kanogawa, Naoya
Ogasawara, Sadahisa
Maruta, Susumu
Iino, Yotaro
Obu, Masamichi
Ishino, Takamasa
Ogawa, Keita
Yumita, Sae
Iwanaga, Terunao
Unozawa, Hidemi
Nakagawa, Miyuki
Fujiwara, Kisako
Sakuma, Takafumi
Fujita, Naoto
Kojima, Ryuta
Kanzaki, Hiroaki
Koroki, Keisuke
Kobayashi, Kazufumi
Inoue, Masanori
Kiyono, Soichiro
Nakamura, Masato
Kondo, Takayuki
Saito, Tomoko
Nakagawa, Ryo
Nakamoto, Shingo
Muroyama, Ryosuke
Chiba, Tetsuhiro
Itobayashi, Ei
Koma, Yoshihiro
Azemoto, Ryosaku
Kato, Jun
Kato, Naoya
Article History
Received: 28 June 2022
Accepted: 13 February 2023
First Online: 11 March 2023
Declarations
:
: All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Formal consent by written signature was not required for this type of study based on Japanese regulations (mhlw.go.jp/content/000909926.pdf). The need for Informed Consent was waived off (retrospective study) by the Chiba University Research Ethics Committee also approved this point. The Chiba University Research Ethics Committee approved this study (No. 3091). An opt-out approach was used to obviate patient informed consent for publication. An opt-out is a method in which, instead of omitting informed consent, research information is notified and disclosed on a website, etc., to ensure that research subjects have the opportunity to refuse.
: Not applicable.
: Sadahisa Ogasawara received honoraria from Bayer, Leverkusen, Germany; Eisai, Tokyo, Japan; Eli Lilly, Indianapolis, IN, USA; Chugai Pharma, Tokyo, Japan; AstraZeneca, Cambridge, UK; and Merck & Co., Inc., Kenilworth, NJ, USA, consulting or advisory fees from Bayer, Eisai, Merck & Co., Inc., Chugai Pharma, Eli Lilly, and AstraZeneca, and research grants from Bayer, AstraZeneca, and Eisai. Naoya Kato received honoraria from Bayer, Eisai, Sumitomo Dainippon Pharma, Tokyo, Japan, and Merck & Co., Inc.; consulting or advisory fees from Bayer and Eisai; and research grants from Bayer and Eisai. The other authors have no conflicts of interest to declare.